Lake Forest, CA — June 2025 Biodynamik was selected as one of the Top 5 finalists in the American Diabetes Association’s (ADA) 2025 Innovation Challenge, gaining the opportunity to present its mission and breakthrough technology during the ADA’s prestigious scientific competition at the 85th Scientific Sessions.

The Innovation Challenge highlights the most promising startups addressing the critical needs of people living with diabetes and its complications. As a finalist, Biodynamik showcased the XT3 System with automated distraction technology to seamlessly perform the Transverse Tibial Bone Transport (TTT) procedure.

Johnny Chen, CEO, represented Biodynamik in the competition and presented the company’s technology. “Recognition from the American Diabetes Association carries tremendous weight. It affirms the importance of our work.” Chen said.

About Biodynamik

Biodynamik, Inc. develops orthopedic external fixation systems. The XT3® System is FDA 510(k) cleared for fracture fixation, nonunion, transverse bone transport of the tibia, and the correction of bony or soft tissue defects and deformities in adult patients. Biodynamik is sponsoring the SMILE-TTT study (IDE G260049) of transverse tibial transport in patients with diabetic foot ulcers; this use is investigational.